NCT03336333 2026-03-09SEQUOIABeOne MedicinesPhase 3 Active not recruiting590 enrolled 12 charts 1 FDA
NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts
NCT03206918 2024-10-26Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaBeiGenePhase 2 Completed91 enrolled 14 charts